A Phase 1 Open-Label Multi-Center Safety and Efficacy Study of PRT3789 as Monotherapy and in Combination with Docetaxel in Participants with Select Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Select Advanced Or Metastatic Solid Tumors With A Smarca4 Mutation
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    To participate in the study the following conditions must be met:
    1. 1) Patients must have cancer that has spread or come back and is confirmed by a tissue sample. The cancer must have a specific genetic change called "loss of SMARCA4" which can b

You may not be eligible for this study if the following are true:

  • You will not be able to participate in the study if you have had:
    1. 1) A medical or mental health condition or a laboratory result that may make it risky for them to take part in the study or could make it hard to understand the study results <

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.